Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation

The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol.